Ann: Neuren announces new appointments to the board of directors, page-2

Neuren announces new appointments to the board of directors
Melbourne, Australia, 4 July 2018: Neuren Pharmaceuticals (ASX: NEU) today announced the
appointment of Dianne Angus, Patrick Davies and Jenny Harry as non-executive directors. The new
directors bring skills, diversity and experience in drug development and commercialisation that are
highly relevant to Neuren as a leading developer of new treatments for neurological disorders.
Following these appointments, the composition of the Neuren board will be 4 independent non-
executive directors and 2 executive directors.
Dianne Angus is currently interim CEO of the Victorian Australian Medical Association (AMA) and was
formerly Chief Operating Officer of the neurological drug development company Prana Biotechnology.
Dianne is also a registered Patent and Trademark Attorney.
Patrick Davies has held executive management roles in the healthcare industry for over twenty years,
including leading Symbion then EBOS Group as CEO for the last ten years through a period of growth in
enterprise value from approximately $450 million to in excess of $3.1 billion.
Dr Jenny Harry is currently CEO of drug development company Ondek and was formerly CEO and
Managing Director of Tyrian Diagnostics, leading its transformation and the commercialisation of its first
diagnostic product.
Neuren Executive Chairman Richard Treagus commented: “Seeking to capitalise on our current strong
position and ensure that the board has the appropriate skills and composition for the future, we have
taken the opportunity to appoint three very talented and highly regarded leaders. We are confident
that the new directors will make an extremely valuable contribution as Neuren continues to execute on
its partnering and drug development activities.